Atomic Force Microscopy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Atomic Force Microscopy
An analytical technique that is receiving increased attention in the pharmaceutical industry is atomic force microscopy. We interview Mark Leaper from the UK's De Montfort University to find out more about this technology.


Pharmaceutical Technology Europe


How can characterisation of the morphology and roughness of pharmaceutical granules using atomic force microscopy result in improved granulation and pharmaceutical processing?

The flow properties of a powder can be influenced by the shape and roughness of the particles. A thorough knowledge of the surface properties of excipient powders and the resulting granules will enable process parameters to be optimised. It will also be helpful when modifying process methods, for example, a switch from wet granulation to dry granulation or direct compression. Rough particles also have a greater surface area, allowing the absorption of more moisture. This may be desirable or undesirable, depending on the application of the powder.

How might AFM be applied to the measurement of dynamic rheological properties, to benefit characterisation of a pharmaceutical formulation?

AFM can be used in liquids, and there have been several studies of suspensions and colloids in which AFM has been used to measure interactions between particles, as well as between the particles and fluid. There have also been studies that have examined the formation of bubbles in liquids and their interaction with particles in the suspension. AFM could be used to complement other techniques in optimising the design and manufacture of pharmaceutical suspensions, creams and lotions. In addition to the properties of the drug delivery systems, AFM can be used to characterise the areas to which the formulations are applied, such as skin, hair or dressing.

Are there any knowledge or technological gaps in the pharma industry that prevent AFM from being fully exploited?

The techniques and research strategies for using AFM in the pharma industry are now well established: examining the properties of powdered excipients, colloids, pulmonary drug delivery, microbiological systems and implants. The volume of data is still limited, however, and has not kept pace with the new formulations. As manufacturing companies modify their practices to accommodate the new quality by design approach, AFM will have a part to play. Along with bulk powder techniques, knowledge of the variation of surface properties will enable optimisation of solid-dosage manufacturing processes.

Mark Leaper is Senior Lecturer, School of Pharmacy,De MontfortUniversity (UK).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here